CX-2051 is a conditionally activated antibody drug conjugate (ADC) directed toward the epithelial cell adhesion molecule (EpCAM). EpCAM is a validated anti-cancer target for which systemic therapies not yet been developed due to widespread expression on normal tissues. CX-2051 is designed to open a therapeutic window for a systemically administered anti-EpCAM ADC. The drug candidate is currently in a Phase 1 dose-escalation study in patients with advanced solid tumors.
Purpose: The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 in adult participants with advanced solid tumors (primarily CRC).
If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.
CX-801 an interferon (IFN) alpha-2b Probody® therapeutic. Interferons are approved anti-cancer therapies but are limited by narrow therapeutic windows. CX-801 is designed to selectively activate within the tumor microenvironment, enhancing anti-tumor immune responses while minimizing systemic toxicity associated with traditional interferon therapies. Based on preclinical studies, CX-801 demonstrated a wide therapeutic index with an enhanced tolerability profile versus unmasked IFN, without compromising its potent antitumor effects. CX-801 may have broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors.
Purpose: The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.
If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.